Breast Cancer Clinical Trials in New York

Showing 361-380 of 838 trials

Milademetan in Advanced/Metastatic Solid Tumors

NCT05012397

Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number (CN) ≥ 8 using prespecified biomarker criteria.

Solid TumorsHead and Neck CarcinomaCholangiocarcinoma+15 more

Rain Oncology Inc40 participantsStarted Nov 2021

Palo Alto, California, United States • Fort Myers, Florida, United States • St. Petersburg, Florida, United States +11 more locations

Active Not RecruitingPhase 1< 1 mile

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Pancreatic CancerBreast CancerGastric Cancer+13 more

NGM Biopharmaceuticals, Inc130 participantsStarted Mar 2022

Gilbert, Arizona, United States • Los Angeles, California, United States • Sarasota, Florida, United States +6 more locations

Milademetan in Advanced/Metastatic Solid Tumors

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Breast Cancer Trials in Other Cities

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Assessing Depression in a Geriatric Cancer Population

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

A Study of ZN-c5 in Subjects With Breast Cancer

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Palbociclib in Real World Practice

Breast Cancer Index (BCI) Registry

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer

Motiva Flora Tissue Expander PMCF

Other Conditions in New York